Chemokines are chemotactic proteins which play a central role in immune and inflammatory responses. Chemokine receptors are members of the seven transmembrane G-protein coupled family and have recently been shown to be involved in the entry of human immunodeficiency virus (HIV) into target cells. To study chemokine endocytosis in detail we have used novel sitespecific chemistry to make a fluorescently labeled CCchemokine agonist (rhodamine-MIP-1␣) and antagonist (NBD-RANTES). We have also generated a CHO cell line stably expressing a hemagglutinin-tagged version of the CC-chemokine receptor 1 (CCR1), and using these reagents we have examined the receptor-mediated endocytosis of CC-chemokines by confocal microscopy. Our studies reveal that the agonist was internalized and accumulated in transferrin receptor-positive endosomes whereas the antagonist failed to internalize. However, receptor-bound antagonist could be induced to internalize by co-administration of agonist. Analysis of receptor redistribution following chemokine addition confirmed that sequestration was induced by agonists but not by antagonists.
1 which in most cases are promiscuous in that they will bind more than one ligand with high affinity (1) . Although receptormediated endocytosis of certain GPCRs such as the ␤ 2 -adrenergic receptor has been well documented, the endocytic pathways utilized by most GPCRs are still uncharacterized. Following stimulation by agonist, the ␤ 2 -adrenergic receptor is rapidly phosphorylated by a specific GPCR kinase. This uncouples the interaction between the receptor and the G-protein and allows binding of ␤-arrestin which acts as an adapter to recruit the receptor into clathrin-coated vesicles (2) . Several studies have shown that GPCRs are internalized via clathrin-coated vesicles, although this may not be a universal mechanism as alternative endocytic pathways have been described for a number of different ligands (3) (4) (5) (6) (7) (8) (9) (10) .
Chemokines such as RANTES (regulated on activation normal T cell expressed and secreted), MIP-1␣, and MIP-1␤ have been shown to be the major HIV-suppressive factors produced by CD8 ϩ T cells (11) , and a number of recent studies have gone on to show that chemokine receptors are co-receptors along with CD4 for the entry of HIV into cells (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . This has raised the possibility of using chemokines therapeutically to block HIV entry. Receptor-mediated endocytosis of chemokines has not been studied in detail, but an understanding of this process is clearly important if we are to develop selective therapeutic agents which block HIV entry into cells. To this end we have studied the receptor-mediated endocytosis of CC-chemokines by CCR1 as a prototype for the CC-chemokine receptor family.
EXPERIMENTAL PROCEDURES
Fluorescent Chemokines-Recombinant chemokines were expressed and purified from a bacterial expression system as described (22) . Fluorescent chromophores were conjugated by chemically coupling to the amino terminus according to the procedures described (23) . The formation of rhodamine-MIP-1 necessitated certain modifications of this technology.
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Receptor Expression-The full length cDNA encoding CCR1 was cloned by reverse transcriptase-PCR from the human eosinophilic cell line EOL-3 using specific primers based on the published sequence (24) . The cDNA was subcloned into a pcDNAneo1-based mammalian cell expression vector (p12ca5) after the addition of the HA epitope tag (YPYDVPYASLRS) to the 5Ј end of the receptor cDNA by PCR. The sequence of the receptor cDNA was verified prior to transfection into CHO-K1 cells. The CHO-K1 cells were maintained in Dulbecco's modified Eagle's medium-F12 medium containing 10% heat-inactivated fetal calf serum, 2 mM glutamine, and 100 units/ml penicillin/streptomycin (complete medium) and were harvested by trypsinization and resuspended at 2 ϫ 10 7 cells/ml in 20 mM HEPES buffer pH 7.3 containing 150 mM NaCl. Five hundred-microliter aliquots of cells were electroporated with 30 g of p12ca5 plasmids containing the receptor cDNA at 260 V, 960 F, using a Bio-Rad Gene Pulser. After electroporation, cells were transferred to fresh medium and allowed to recover for 48 h before addition of 600 g/ml geneticin (G418). Fourteen days after electroporation, individual G418-resistant colonies were isolated by ring cloning and maintained in complete medium containing G418. Individual clones were then tested for binding to the anti-HA monoclonal antibody 12CA5 (Boehringer), and cells expressing high levels of receptor were selected by a fluorescence-activated cell sorter using an anti-mouse fluorescein isothiocyanate conjugate. The resultant cell population was designated CHO-CCR1 and was subsequently maintained in complete medium.
Chemotaxis Assays-Biological activity of the chemokines or modified chemokines was assessed by their ability to induce monocyte chemotaxis in micro-Boyden chambers as described previously (22, 25) . Assays were performed either on the THP-1 cell line or on human peripheral blood monocytes. * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Immunofluorescence Confocal Microscopy-All experiments were performed on CHO-CCR1 cells grown overnight on chamber slides (Nunc). For chemokine endocytosis experiments the cells were washed twice with ice-cold buffer (phosphate-buffered saline with 1% bovine serum albumin). Fluorescent chemokines (500 nM) were incubated with the cells for 4 h on ice followed by three washes in ice cold buffer to remove unbound ligand. Fresh medium was added, and the cells were either kept at 4°C or incubated at 37°C for 15 or 30 min. At the end of this incubation cells were fixed, permeabilized, and processed for confocal microscopy by standard procedures. For immunofluorescence studies following incubation with chemokines the fixed cells were permeabilized and incubated with an anti-transferrin receptor monoclonal antibody (H68.4, a kind gift from Professor Colin Hopkins, Laboratory for Molecular Cell Biology, University College London) or with the anti-HA antibody 12CA5 (Boehringer). All slides were examined with a Leica TCS4 confocal scanning laser microscope.
RESULTS AND DISCUSSION
To study CC-chemokine endocytosis we generated fluorescently labeled RANTES and MIP-1␣ using site-specific chemistry to attach the fluorophore specifically to the terminal amino group of the polypeptide chain (23, 26) . Using this technique we conjugated rhodamine to MIP-1␣ and 7-nitrobenz-2-oxa-1,3-diazole-4-yl (NBD) to RANTES. These fluorescently labeled CC-chemokines retained their ability to bind specifically to CCR1 although the binding affinity was slightly reduced compared with the unmodified agonist (23, 26) . Prior to using these ligands to study endocytosis we assessed their biological activity in chemotaxis assays. Rhodamine-MIP-1␣ acted as a full agonist and induced maximal chemotaxis at a concentration of 100 nM (Fig. 1A) . However, NBD-RANTES had no biological activity in a chemotaxis assay. We have previously shown that modification of the amino terminus of RANTES has a profound influence on its biological properties (25) . Failure to cleave the initiating methionine from bacterially expressed RANTES (Met-RANTES) produced a protein which was devoid of agonist activity but was a potent antagonist. Similarly, conjugation of the fluorophore NBD to the amino terminus of RANTES also converted it from an agonist to an antagonist. As shown in Fig. 1B both Met-RANTES and NBD-RANTES can fully antagonize the chemotactic activity of RANTES on THP-1 cells.
For endocytosis studies the human CCR1 cDNA was cloned by reverse transcriptase-PCR, and an HA epitope tag was placed at the extreme amino terminus. The tagged receptor was transfected into CHO cells, and lines stably expressing the receptor were cloned. Radioligand binding assays confirmed that the tagged CCR1 expressed in CHO cells (CHO-CCR1) retained high affinity ligand binding and ligand specificity (data not shown). In the initial experiments the fluorescent rhodamine-MIP-1␣ and NBD-RANTES were bound to CHO-CCR1 cells for 4 h at 4°C at a final concentration of 500 nM. Unbound ligand was washed off with ice-cold buffer prior to warming the cells to 37°C for timed periods up to 30 min (Fig.  2) . The agonist, rhodamine-MIP-1␣, was effectively internalized and accumulated in perinuclear vesicles (panels A-C) whereas the antagonist, NBD-RANTES, remained almost entirely on the cell surface (panels D-F). This is consistent with other GPCRs for which it has been shown that receptor internalization is dependent upon agonist stimulation and is inhibited by antagonists (4, 6, 9, 10). However, since we have made NBD-RANTES we were able to perform the experiment to study the effect of agonist stimulation upon the receptor-mediated endocytosis of a fluorescent antagonist. Binding of NBD-RANTES in the presence of an equimolar concentration of RANTES showed that the antagonist could be induced to cluster and internalize in the presence of agonist (panels G-I). Although the internalized antagonist appeared in more peripheral endosomes rather than in the perinuclear structures in which the agonist accumulated, this observation nonetheless demonstrated that agonist-bound receptor could induce the sequestration of antagonist-occupied receptor. These findings suggest that activation of the GPCR kinase by agonist will induce phosphorylation, and consequently sequestration, of receptors occupied by agonists or antagonists. The significance of this relates to how a virus uses a GPCR to gain entry to a cell. These findings suggest that HIV would not have to act as an agonist to be internalized via CC-chemokine receptors provided there is sufficient chemokine agonist present to induce receptor internalization. This is consistent with recent findings, using chimeric receptors, that the regions of CCR5 required for viral entry and for chemokine signal transduction are distinct (27) . It may also explain the observation that in certain macrophage cultures addition of CC-chemokines actually enhances rather than inhibits HIV replication (28) .
To define the endocytic compartment into which rhodamine-MIP-1␣ was being delivered we performed dual-labeling studies with the transferrin receptor. Rhodamine-MIP-1␣ was bound to CHO-CCR1 cells at 4°C, and receptor-bound ligand was subsequently allowed to internalize for 30 min at 37°C. Cells were fixed, permeabilized, and stained using an antibody to the transferrin receptor (Fig. 3) . Analysis of the cells by confocal microscopy revealed that at 4°C, the rhodamine-MIP-1␣ decorated the plasma membrane (panel B) whereas the transferrin receptor staining was both on the plasma mem- 
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Following a 30-min warm up the rhodamine-MIP-1␣ was internalized into perinuclear endosomal vesicles (panel D) and showed an exact co-localization with the transferrin receptor (panel C).
Since it is well documented that the transferrin receptor is a marker for the clathrin-coated pit endocytic pathway it is reasonable to conclude that the CCR1 is also internalized via this mechanism.
As a final study we decided to examine the receptor redistribution following addition of agonist or antagonist. For these experiments various chemokines were added to CHO-CCR1 cells at 37°C for 30 min after which time the cells were washed, fixed, and permeabilized, and the CCR1 receptor was visualized by staining with the anti-HA monoclonal antibody (Fig. 4) . The various chemokines were added at a concentration of either 50 nM or at 1 M. Without chemokine addition the receptor was predominantly seen on the plasma membrane (panel A) and addition of the antagonists NBD-RANTES (panels B and C) or Met-RANTES (panels D and E) did not induce any significant receptor redistribution. However the agonists MIP-1␣ (panels F and G) and RANTES (panels H and I) both induced receptor sequestration, although MIP-1␣ appeared more effective in this respect than RANTES. Even at 50 nM, MIP-1␣ induced most of the CCR1 to redistribute from the plasma membrane to perinuclear vesicles, and at 1 M receptor downregulation was almost complete. These observations are the first detailed description of chemokine and chemokine receptor endocytosis, and they show that CCR1 is likely to be internalized via clathrin-coated pits. We demonstrate that both ligand and receptor accumulate in perinuclear endosomes and that receptor internalization is dependent upon agonist stimulation. Provided that all CC chemokine receptors behave like CCR1, does this give us any insight into how we might use chemokines as therapeutic agents to prevent HIV entry into cells? The protective effects of chemokines may be due to two factors. The chemokine may act as a competitive inhibitor preventing binding of the virus to the receptor or it may down-regulate surface receptors so that there are no receptors available for the virus. If the second explanation were true then antagonists, which do not induce receptor sequestration, would not be expected to block HIV entry. Recently published data (29) and our own studies 3 confirm that chemokine antagonists are effective at inhibiting HIV entry into target cells. Consequently our study strongly suggests that the observed HIV suppressive effects of chemokines are due to competitive inhibition for receptor binding and not due to receptor down-regulation. These findings have significant implications for the design and discovery of novel therapeutic agents targeted at blocking HIV entry into cells.
